Abaloparatide Decreased Fractures in Postmenopausal Women With Osteoporosis

Summary and Clinical Applicability

In this study of postmenopausal women with osteoporosis, treatment with abaloparatide increased BMD in the lumbar spine, femoral neck, and total hip in a dose-dependent fashion.

“These data suggest that abaloparatide may have potential to provide protection against fractures consistently across a wide variety of ages and baseline risks, including those with and without prior fractures, as well as utility for a broad group of patients with osteoporosis,” the study authors concluded.

Related Content

Radius Health, developer of abaloparatide, filed a new drug application for abaloparatide with the US Food and Drug Administration on March 30, 2016.

Limitations and Disclosures

These results were presented at the ENDO 2016, the annual meeting of the Endocrine Society, and have yet to undergo peer review prior to journal publication.

Radius Health funded this trial. Authors of this study disclosed relationships with Radius Health, Amgen, Eli Lilly, Merck, and Nordic Biosciences.

Reference

Cosman F, Hattersley G, Miller PD, et al. OR-1-2. Abaloparatide Significantly Reduces Vertebral and Nonvertebral Fractures and Increases BMD Regardless of Baseline Risk. Presented at: ENDO 2016; April 1-4, 2016; Boston, MA.

This article originally appeared on Rheumatology Advisor